Novartis announced that it has commenced shipment of its seasonal influenza vaccine, Fluvirin (trivalent inactivated “split virus” influenza vaccine [types A and B]), to customers in the US for the 2012–2013 influenza season.
For the 2012–2013 season, Fluvirin contains antigens that target three influenza virus strains identified by World Health Organization (WHO) experts as likely to dominate circulation. These include:
- A/California/7/2009 (H1N1)-like virus
- A/Victoria/361/2011 (H3N2)-like virus
- B/Wisconsin/1/2010-like virus (from the B/Yamagata lineage of viruses)
Fluvirin vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons ≥4 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
For more information call (800) 693-9993 or visit www.novartis.com.